Cancelled by the investigator A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)

A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003048

Enrollment

Unknown

Registered

2020-02-23

Start date

2020-02-24

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Traditional Chinese medicine soup

Control group:Western antiviral

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) All patients were diagnosed with a new type of coronavirus pneumonia; (2) Clear mind, cooperation and communication; (3) Men and women aged 18 and 80 years; (4) informed consent has been signed and is willing to be assessed.

Exclusion criteria

Exclusion criteria: (1) with severe liver or kidney failure or other serious underlying diseases; (2) Pregnant and lactating women; (3) Persons who are participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Routine urine test;Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Stool routine test;	—

Secondary

Measure	Time frame
renal function;Liver function test;	—

Countries

China

Contacts

Public ContactYuan Yongming

Shenzhen national medicine inheritance medical research institute co. LTD

64699629@qq.com+86 18664556429

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026